Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Thursday. The brokerage issued a hold rating on the stock.

A number of other research firms have also weighed in on EKSO. HC Wainwright restated a buy rating and set a $10.00 price target on shares of Ekso Bionics in a research report on Tuesday, July 30th. Lake Street Capital began coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They issued a buy rating and a $2.50 target price on the stock.

Ekso Bionics Price Performance

Shares of Ekso Bionics stock opened at $1.06 on Thursday. The stock has a market capitalization of $19.26 million, a P/E ratio of -1.09 and a beta of 1.45. The business has a 50 day simple moving average of $1.09 and a two-hundred day simple moving average of $1.18. Ekso Bionics has a 12 month low of $0.74 and a 12 month high of $3.13. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, July 29th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. The firm had revenue of $4.95 million during the quarter, compared to analyst estimates of $5.34 million. During the same period in the prior year, the company posted ($0.31) earnings per share. As a group, analysts predict that Ekso Bionics will post -0.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its position in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.